US equities |
MU $895.47 ▼-3.84% TSLA $368.68 ▲+1.72% AAPL $343.46 ▲+0.43% NVDA $216.28 ▼-0.44% SPCX $146.51 ▼-1.42% SNDK $1,330.67 ▼-4.60% MSFT $536.01 ▼-0.64% AMD $544.29 ▼-3.19%
FinancialContent

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

29.03 -0.61 (-2.06%)
Delayed Quote Updated: 10:07 AM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pharvaris N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema 
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Outlines 2025 Strategic Priorities
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
Data from randomized clinical studies and long-term extension studies support deucrictibant’s potential best-in-class profile, detailing its injectable-like efficacy, placebo-like tolerability, and... 
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Host Virtual Investor Event on October 23, 2024
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Data at the Bradykinin Symposium 2024
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
From Pharvaris N.V.
Via GlobeNewswire
News headline image
PHVS Stock Earnings: Pharvaris Beats EPS for Q2 2024 ↗
PHVS stock results show that Pharvaris beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense ↗
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
Via Investor's Business Daily
News headline image
Pharvaris Announces Annual Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
News headline image
PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024 ↗
PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023 ↗
PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >